{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:46:59Z","timestamp":1783745219054,"version":"3.55.0"},"reference-count":22,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2016,10]]},"abstract":"Objectives<\/jats:title>To evaluate the efficacy and toxicity profiles of everolimus in Japanese patients with renal angiomyolipoma associated with tuberous sclerosis complex.<\/jats:p><\/jats:sec>Methods<\/jats:title>Patients with a 4\u2010cm or larger angiomyolipoma<\/jats:styled-content> meeting the diagnostic criteria of tuberous sclerosis complex<\/jats:styled-content> were selected as participants of our investigation. In each case, we assessed tuberous sclerosis complex<\/jats:styled-content>\u2010associated symptoms, the treatment effect and adverse events. The treatment effect was evaluated by measuring the tumor volume reduction rate using abdominal computed tomography<\/jats:styled-content> or magneitc resonance imaging<\/jats:styled-content>. Adverse events were investigated using CTCAE<\/jats:styled-content> v4.0\u2010JCOG<\/jats:styled-content>. The dose of everolimus was set at 10 mg once a day for adults. For childhood angiomyolipoma<\/jats:styled-content>, everolimus administration was initiated at a dose of 5 mg once a day. Blood everolimus level was measured, and the dose was adjusted to maintain this within a range of 5\u201315 ng\/mL<\/jats:styled-content>.<\/jats:p><\/jats:sec>Results<\/jats:title>The angiomyolipoma<\/jats:styled-content> volume decreased in 46 of 47 cases, and the mean reduction rate for all cases was 60% in 12 months. The angiomyolipoma<\/jats:styled-content> volume markedly decreased in the first 3 months, and the size leveled off after 6 months. The main adverse events related to everolimus treatment were stomatitis (91%) and irregular menstruation (65%). Grade 3 or severer adverse events were noted in three cases (6%). All patients developed some adverse events in the first 6 months. The incidence markedly decreased to 40\u201350% after 13 months.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>The tumor volume\u2010reducing effect of everolimus in a Japanese population was equivalent to or higher than that in Western populations. A wide variety of everolimus treatment\u2010related adverse events can be observed, but most cases are very mild. Special attention should be given to stomatitis, irregular menstruation and interstitial lung disease as adverse events.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.13168","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T18:18:01Z","timestamp":1470161881000},"page":"833-838","source":"Crossref","is-referenced-by-count":24,"title":["Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan"],"prefix":"10.1111","volume":"23","author":[{"given":"Takashi","family":"Hatano","sequence":"first","affiliation":[{"name":"Department of Urology JR Tokyo General Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Chikaraishi","sequence":"additional","affiliation":[{"name":"Department of Urology JR Tokyo General Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Inaba","sequence":"additional","affiliation":[{"name":"Department of Urology JR Tokyo General Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Urology JR Tokyo General Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Egawa","sequence":"additional","affiliation":[{"name":"Department of Urology Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1991.tb37754.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.26.1.28"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063910"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.05.004"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90618-Z"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5327.805"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.5482"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.07.058"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diii.2013.01.003"},{"key":"e_1_2_8_11_1","first-page":"11","article-title":"Guidelines for diagnosis and management of AMLs in TSC","volume":"18","author":"Kingswood C","year":"2013","journal-title":"Br. J. Renal Medicine"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2251011477"},{"key":"e_1_2_8_13_1","first-page":"255","article-title":"Tuberous sclerosis complex surveillance and management: recommendation of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"2013","author":"Krueger DA","year":"2012","journal-title":"Pediat. Neurol."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/1099-0801(200010)14:6<422::AID-BMC25>3.0.CO;2-I"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001853"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61767-X"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv249"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.4329\/wjr.v8.i3.308"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022171"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2006.00423.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-6135.2003.00279.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045868"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.13168","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.13168","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.13168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:25:14Z","timestamp":1696346714000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.13168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/iju.13168"],"URL":"https:\/\/doi.org\/10.1111\/iju.13168","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}